FOLD Q2 2024 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$127M+34.0% YoY

Gross Profit

$115M91.1% margin

Operating Income

$15M11.8% margin

Net Income

-$16M-12.4% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+14.7%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$22M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$749M

Total Liabilities

$617M

Stockholders' Equity

$133M

Cash & Equivalents

$209M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$127M	$95M	+34.0%
Gross Profit	$115M	$85M	+35.2%
Operating Income	$15M	-$19M	+179.4%
Net Income	-$16M	-$43M	+63.7%

Geographic Segments

Non-US

$77M60%

UNITED STATES

$50M40%